Wegovy vs Zepbound: A Clinical Comparison of Modern Weight Loss Medications

By Matt Waterman · 2026-07-11

Wegovy (semaglutide) and Zepbound (tirzepatide) are both FDA-approved prescription medications for chronic weight management in adults with a BMI of 30 or greater, or 27 with a weight-related comorbidity. While both belong to the class of GLP-1 receptor agonists, Zepbound acts as a dual-agonist by also targeting the GIP receptor, which may lead to higher average weight loss percentages according to clinical trials. Choosing between them requires a clinical evaluation of your metabolic health, history with side effects, and insurance coverage.

How do Wegovy and Zepbound differ in their mechanism of action?

Wegovy contains semaglutide, a selective GLP-1 receptor agonist. It mimics the naturally occurring glucagon-like peptide-1 hormone, which is released by the intestines after eating. This hormone targets areas of the brain that regulate appetite and food intake. By activating these receptors, Wegovy increases feelings of fullness, delays gastric emptying, and helps patients adhere to a reduced-calorie diet.

Zepbound contains tirzepatide, which is chemically distinct because it is a dual agonist. It targets the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. GIP is another hormone involved in energy balance and lipid metabolism. By activating both pathways, Zepbound may provide a synergistic effect on glucose regulation and fat breakdown, which explains the significant weight loss observed in clinical settings compared to single-hormone agonists. If you want the specifics, read oral semaglutide weight loss reviews.

Which medication is more effective for weight loss?

When looking at clinical data, Zepbound often shows a lead in total percentage of body weight lost. In the manufacturer's SURMOUNT-1 clinical trial, participants on the highest dose (15 mg) of tirzepatide lost an average of 20.9 percent of their body weight over 72 weeks. This is a significant benchmark for non-surgical weight loss interventions. Users can find more details via the HELiXVi GLP-1 program to see if these results align with their goals. For a deeper look, see our guide to tirzepatide vs semaglutide for weight loss.

Wegovy is also highly effective. The STEP 1 clinical trial demonstrated that participants taking 2.4 mg of semaglutide lost an average of 14.9 percent of their body weight over 68 weeks. While this is lower than the tirzepatide averages, Wegovy remains a gold standard for patients who may not need dual-hormone activation or who respond better to semaglutide's specific molecular profile. Both medications are meant to be used alongside lifestyle modifications including diet and exercise.

Feature	Wegovy (Semaglutide)	Zepbound (Tirzepatide)
Mechanism	GLP-1 Receptor Agonist	GLP-1 and GIP Dual Agonist
Delivery	Once-weekly Injection	Once-weekly Injection
Max Maintenance Dose	2.4 mg	15 mg
Avg. Weight Loss (Trials)	Approx. 15%	Approx. 21%
Primary Side Effects	Nausea, Vomiting, Constipation	Nausea, Diarrhea, Decreased Appetite

What is the titration schedule for these injections?

Injection titration is the process of gradually increasing your medication dose over several months. This is critical for both Wegovy and Zepbound to allow the body to adjust to the hormone levels and minimize gastrointestinal distress. Wegovy typically starts at 0.25 mg weekly for the first month, followed by 0.5 mg, 1.0 mg, 1.7 mg, and finally the maintenance dose of 2.4 mg. If you experience severe symptoms, your live AI video doctor may suggest staying at a lower dose for an extra month.

Zepbound follows a similar five-step escalation. It begins at 2.5 mg weekly for four weeks to initiate the metabolic response without overwhelming the system. The dose increments by 2.5 mg every four weeks (5 mg, 7.5 mg, 10 mg, 12.5 mg) until reaching the target maintenance dose, which can range from 5 mg to 15 mg based on patient tolerance and efficacy. Rushing this process can lead to significant discomfort and potential discontinuation of the therapy.

Common side effects and how to manage them

The most frequent side effects for both Wegovy and Zepbound are gastrointestinal. This occurs because both drugs slow down gastric emptying, meaning food stays in your stomach longer. Patients frequently report nausea, diarrhea, vomiting, and constipation. These effects are often most prominent in the first 48 hours after an injection or immediately following a dose increase. You can read more about mitigation strategies in our related HELiXVi guide on managing GLP-1 side effects.

Clinical monitoring is essential to watch for rare but serious risks, such as pancreatitis, gallbladder problems, or kidney issues related to dehydration from vomiting. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use these medications. Proper hydration and eating smaller, protein-rich meals can help mitigate most mild to moderate side effects during the first few months of treatment.

Availability and the role of telehealth

Securing these medications can sometimes be a challenge due to high demand and supply chain constraints. This is where telehealth platforms provide a distinct advantage. A virtual consultation allows for a comprehensive review of your medical history and BMI eligibility without the need for an in-person office visit, which is especially helpful for patients in remote areas or with busy schedules.

Telehealth providers can also assist in navigating insurance hurdles. Since Wegovy and Zepbound are high-cost specialty medications, many insurance providers require a prior authorization. If insurance coverage is not available, your doctor can discuss alternative pathways or help you understand the out-of-pocket cost structures. HELiXVi provides a streamlined approach to medical weight management for US-based patients only. To begin your journey, complete our medical intake at the GLP-1 program link.

What switching between them actually involves

Patients who start on one agent and later move to the other rarely transfer at an equivalent dose. Because semaglutide and tirzepatide act on different receptor profiles, semaglutide on the GLP-1 receptor alone and tirzepatide on both GIP and GLP-1 receptors, tolerance built to one does not fully carry across. A switch normally means restarting near the introductory dose of the new medication and titrating upward again, which can mean a temporary return of early gastrointestinal symptoms.

That reset is worth planning for rather than discovering mid-course. It usually adds several weeks before reaching a maintenance dose, and appetite suppression may be weaker during the transition. Clinical reasons to consider switching include persistent side effects at a low dose, an inadequate response after a genuine trial at an adequate dose, or supply and cost changes. Preference alone is a weaker reason if the current treatment is working well and is tolerated.

Whichever agent is used, the evidence is consistent that weight regain is common when treatment stops without a maintenance plan. Both medications are studied as long-term therapies alongside diet and activity, not as short courses, and that expectation should shape the decision from the outset rather than being addressed at the end.

This article is educational and is not a substitute for individual medical advice. A HELiXVi physician determines what is appropriate for you.